CXCR4-targeted [ 68 Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [ 18 F]FDG.
Zitong Zhang, Haoyuan Hu, Xin Li et al.
✦ AI-curated · Sources linked
In 30 seconds
[ 68 Ga]Ga-PentixaFor PET/CT was evaluated in a prospective study of 41 treatment-naïve patients with marginal zone lymphoma (MZL) to compare its effectiveness against [ 18 F]FDG. The study found that [ 68 Ga]Ga-PentixaFor had significantly higher lesion detection rates, particularly in gastric and nodal involvement, and resulted in disease upstaging in 26.8% of patients, with management changes in 56.1%.
Key findings
- [ 68 Ga]Ga-PentixaFor detected lesions in 72.0% of gastric cases compared to 40.0% for [ 18 F]FDG.
- Nodal involvement detection rates were 97.4% for [ 68 Ga]Ga-PentixaFor versus 39.7% for [ 18 F]FDG.
- Management modifications occurred in 56.1% of patients after [ 68 Ga]Ga-PentixaFor imaging.
- Higher baseline [ 68 Ga]Ga-PentixaFor SUVmax (> 7.96) correlated with lower complete remission rates.
Why it matters
Accurate staging and risk stratification in marginal zone lymphoma are crucial for effective management. This study highlights the potential of [ 68 Ga]Ga-PentixaFor PET/CT to enhance diagnostic accuracy and influence treatment decisions, which may lead to improved patient outcomes.